9LBA A randomized phase III study comparing gefitinib with carboplatin (CBDCA) plus paclitaxel (TXL) for the first-line treatment of non-small cell lung cancer (NSCLC) with sensitive EGFR mutations: NEJ002 study
A. Inoue, K. Kobayashi, M. Maemondo, S. Sugawara, S. Oizumi, Y. Saijo, A. Genma, S. Morita, K. Hagiwara, T. NukiwaVolume:
7
Year:
2009
Language:
english
DOI:
10.1016/s1359-6349(09)72038-5
File:
PDF, 46 KB
english, 2009